CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms

Fouad, Neveen Bahaa El Din; Ibrahim, Noha; Aziz, Rania S. Abdel; Ibrahim, S.

doi:10.31557/apjcp.2018.19.12.3383

Cited by 21 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with this, absence of the CD200/CD200R inhibitory axis results in enhanced anti-tumor responses (Kretz-Rommel et al, 2007;McWhirter et al, 2006;Petermann et al, 2007;Rygiel et al, 2012). Coherently, tumor CD200 expression in multiple human cancers is associated with poor prognosis (Aref et al, 2018;Chen et al, 2017;El Din Fouad et al, 2018;Moreaux et al, 2006) and blocking the CD200/CD200R inhibitory axis has been proposed as checkpoint blockade therapy in human cancer (Mahadevan et al, 2019).…”

Section: Introductionmentioning

confidence: 80%

Inhibitory CD200-receptor signaling is rewired by type I interferon

Vlist

Ramos

Hoogen

et al. 2020

Preprint

View full text Add to dashboard Cite

CD200 Receptor 1 (CD200R) is an established inhibitory immune receptor that inhibits TLRinduced cytokine production through Dok2 and RasGAP. RasGAP can be cleaved under certain conditions of mild cellular stress. We found that in the presence of cleaved RasGAP, CD200R loses its capacity to inhibit rpS6 phosphorylation. Furthermore, IFNα prestimulation of human mononuclear cells results in increased amounts of cleaved RasGAP.Coherently, upon pretreatment with increasing concentrations of IFNα, CD200R gradually shifts from an inhibitor to a potentiator of TLR7/8-induced IFNG mRNA production. In peripheral blood mononuclear cells from Systemic Lupus Erythematosus (SLE) patients, a prototypic type I IFN disease, we found an increased proportion of cleaved RasGAP compared to healthy controls. In line with this, in subsets of SLE patients the inhibitory function of CD200R is lost or converted to a potentiating signal for IFNG mRNA production.Thus, our data show that type I IFN rewires CD200R signaling and suggest that this cellextrinsic regulation of signaling could contribute to perpetuation of inflammation in SLE.

show abstract

Section: Introductionmentioning

confidence: 80%

Inhibitory CD200-receptor signaling is rewired by type I interferon

Vlist

Ramos

Hoogen

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…As reported in Table 3, correlations were found with some clinical-biological features of CLL patients with <50% CD200+ cells. In contrast, using the same methodological approach, El Din Fouad et al found other correlations in patients with a lower percentage of CD200+ CLL cells (<50%) (74). Moreover, while the former study did not report data on TTT, response to therapy or OS, the latter found no correlation with response to treatment or OS.…”

Section: Cd200 and Prognosis In Cllmentioning

confidence: 89%

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance

D’Arena¹,

Feo

Pietrantuono

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

CD200, a transmembrane type Ia glycoprotein belonging to the immunoglobulin protein superfamily, is broadly expressed on a wide variety of cell types, such as B lymphocytes, a subset of T lymphocytes, dendritic cells, endothelial and neuronal cells. It delivers immunosuppressive signals through its receptor CD200R, which is expressed on monocytes/myeloid cells and T lymphocytes. Moreover, interaction of CD200 with CD200R has also been reported to play a role in the regulation of tumor immunity. Overexpression of CD200 has been reported in chronic lymphocytic leukemia (CLL) and hairy cell leukemia but not in mantle cell lymphoma, thus helping to better discriminate between these different B cell malignancies with different prognosis. In this review, we focus on the role of CD200 expression in the differential diagnosis of mature B-cell neoplasms and on the prognostic significance of CD200 expression in CLL, where conflicting results have been published so far. Of interest, increasing evidences indicate that anti-CD200 treatment might be therapeutically beneficial for treating CD200-expressing malignancies, such as CLL.

show abstract

“…Alterations between OX2 and its OX2R receptor were found in both PD and AD. Precisely in this regard, studies have been carried out to study how the OX2-OX2R system determines a greater probability of the appearance of neurodegenerative diseases [67,90]. The well-established PD model that leads to the neurodegeneration of dopaminergic neurons is induced by intragastrically administered rotenone [91] or 6-hydroxydopamine (6-OHDA).…”

Section: Orexin In Microglia Activationmentioning

confidence: 99%

Role of Vitamin E and the Orexin System in Neuroprotection

et al. 2021

View full text Add to dashboard Cite

Microglia are the first line of defense at the level of the central nervous system (CNS). Phenotypic change in microglia can be regulated by various factors, including the orexin system. Neuroinflammation is an inflammatory process mediated by cytokines, by the lack of interaction of specific receptors such as the OX2-OX2R complex, caused by systemic tissue damage or, more often, associated with direct damage to the CNS. Chronic activation of microglia could lead to long-term neurodegenerative diseases. This review aims to explore how tocopherol (vitamin E) and the orexin system may play a role in the prevention and treatment of microglia inflammation and, consequently, in neurodegenerative diseases thanks to its antioxidant properties. The results of animal and in vitro studies provide evidence to support the use of tocopherol for a reduction in microglia inflammation as well as a greater activation of the orexinergic system. Although there is much in vivo and in vitro evidence of vitamin E antioxidant and protective abilities, there are still conflicting results for its use as a treatment for neurodegenerative diseases that speculate that vitamin E, under certain conditions or genetic predispositions, can be pro-oxidant and harmful.

show abstract

CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms

Cited by 21 publications

References 14 publications

Inhibitory CD200-receptor signaling is rewired by type I interferon

Inhibitory CD200-receptor signaling is rewired by type I interferon

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance

Role of Vitamin E and the Orexin System in Neuroprotection

Contact Info

Product

Resources

About